NewsBenzingaOppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94 Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94 Benzinga 2026.11.03 17:11 (GMT+0) Open on Benzinga Other news Fermium Research Maintains Buy on DuPont de Nemours, Raises Price Target to $160 Morgan Stanley Maintains Equal-Weight on Allegion, Raises Price Target to $181 Morgan Stanley Maintains Overweight on Advanced Energy Indus, Lowers Price Target to $368 Truist Securities Reiterates Hold on V2X, Raises Price Target to $87 Anthropic is still grappling with the economics of compute Truist Securities Reiterates Buy on Tenet Healthcare, Raises Price Target to $305
